Between Visits: FAQs with Experts: DLBCL

A Patient-Led Guide to Diffuse Large B-Cell Lymphoma (DLBCL)

Our “Office Hours” are designed to feel like a conversation with a well-informed friend who actually listens. We dive deep into the questions patients actually ask, translating complex clinical data into actionable steps for your care.

Move from overwhelmed to empowered as you listen in to leading experts answer patients’ most pressing questions.

Program Experts

  • Dr. Tycel Phillips
    Associate Professor, Division of Lymphoma
    City of Hope, Los Angeles, CA
  • Dr. Robyn Stacy-Humphries
    DLBCL Patient Advocate & Radiologist

Program Topics

  • Understanding Your Diagnosis: Why DLBCL is the most common non-Hodgkin lymphoma and how its “aggressive” nature actually makes it more treatable and curable.
  • The “Alphabet Soup” Decoded: An expert breakdown of standard frontline treatments like R-CHOP and the newer Pola-R-CHP—and what they mean for your daily life.
  • Fueling Your Recovery: Why “calories are king” during treatment and how simple movement (like walking) can help you overcome chemo-fatigue (extreme exhaustion caused by treatment).
  • Advocating for Your Future: How to talk to your care team about advanced options like CAR T-cell therapy (using your own immune cells to fight cancer) if the first treatment doesn’t work.

Program Partner

Blood Cancer United partnership logo

Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trialsresources, and dedicated support through their Information Specialists.

This is not medical advice. Please consult with your healthcare provider to make informed treatment decisions.

This interview has been edited for clarity and length. The views and opinions expressed in this interview do not necessarily reflect those of The Patient Story. This content does not replace professional medical advice.


Hear from people living with diffuse large B-cell lymphoma (DLBCL)

Real experiences with diagnosis, treatment choices, side effects, and life beyond DLBCL — in their own words.